Abstract: The present disclosure relates to adapter assemblies for use with and to electrically and mechanically interconnect electromechanical surgical devices and surgical reloads, and to surgical systems including handheld electromechanical surgical devices and adapter assemblies for connecting surgical reloads to the handheld electromechanical surgical devices.

Abstract: Methods and apparatus, including computer program products, are provided for express voting. In some example embodiments, there is provided a method for express voting. The method may include authenticating a voter based on a token carried by a user equipment, the token mapped to at least one of an identity of the voter, a precinct of the voter, and a ballot for the voter; and providing, when the authenticating indicates the voter is authorized to vote, the ballot presented on the user equipment. Related systems, methods, and articles of manufacture are also disclosed.

Abstract: Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.

Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence or a human cytomegalovirus (huCMV) intron A sequence. Some of the vectors are useful for inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and methods of producing a protein of interest, in vitro, involving the mammalian host cell.

Abstract: There is provided a device, a method and a system for managing and monitoring the medication of a patient. The medication storage and retrieval device (21) for managing and monitoring use of medication, the device (21) comprises a housing (122); a movable support (123) coupled to the housing; one or more containers (1) removably positionable within the housing of the device locatable on the support, each container being configured to store a medication, the medication provided in a loose form such as tablets or pills. The device (21) has a first closed configuration when the movable support (123) and containers thereon (1) are stowed within the housing, and a second open configuration when the movable support (123) and said containers (1) thereon are located outside the housing for access by a user to allow retrieval of medication from a container, as required.

Abstract: The present application relates to a medical management system (100) and method for managing and tracking medical and/or clinical events associated with a patient such as vaccine administration, medicament administration, drug trial, and the like. The medical management system (100) comprises a pathogen care management platform (110), which is communicatively coupled to at least one electronic device (150 1-n) and at least one pathogen care device (120 1-n). The electronic device (150 1-n) is configured to identify the patient prior to a medical and/or clinical event, while the pathogen care device (120 1-n) is configured to detect a deposit of a pathogen care item associated with the medical event. The PCM platform (110) is configured to receive the information generated by at least one electronic device (150 1-n) and at least one pathogen care device (120 1-n) and accordingly update a digital health data record of the user.

Abstract: A point of care device for supporting management of medication at a point of care location is provided, comprising: a container defining an interior space accessible via an opening and a sensor system. A sensor system coupled to the container includes one or more vibration sensors, a memory, and a power supply. The vibration sensors (i) detect vibrations or movements resulting from end-user interactions with the container and (ii) output vibration signal data indicative of the vibrations detected. The memory stores the vibration signal data over a defined time period. In a first point of care mode, the container receives and contains used medication delivery devices into the interior space, and to contain said used medication delivery devices therein. In a second processing mode, the container allows access to the interior space for removal of the used medication delivery devices.

Abstract: The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

Abstract: A system includes a medical item affixed with an electronically readable label, and a receptacle having a sensor configured to read the electronically readable label and communicate data pertaining to the electronically readable label with a server-based medical adherence application.

Abstract: A cartridge includes a case housing a smartphone, a housing configured to hold a medication blister pack, and a detection method to record the blister pack being put in and out of the housing.

Abstract: Methods and apparatus for a sharps medical adherence lid. A sharps medical adherence lid includes a housing, and a clasping device, the clasping device configured to removably attach the housing to a medical sharps bin, the housing including an upper latch, a spring loaded hinged door secured by the upper latch, a slide adapted to capture an object passing through the spring loaded hinged door, a lower opening configured to receive the object from the slide and enable it to pass in the medical sharps bin.

Abstract: A system includes a smartphone, a connected sharps container, the connected sharps container communicatively linked to the smartphone, and a web server, the web server communicatively linked to the smartphone and to the connected sharps container.

Abstract: A method of producing a printed electronic device on a thin PDMS film which includes coupling a first layer of a water-soluble polymer to a substrate and drying the first layer of the water-soluble polymer. The method further includes coupling a second layer of a crosslinkable PDMS polymer to the first layer of the water-soluble polymer and curing the second layer of the crosslinkable PDMS polymer to form the thin PDMS film. The method also includes printing one or more functional layers on the thin PDMS film and drying the one or more functional layers on the thin PDMS film to form the printed electronic device coupled to the substrate.

Abstract: Disclosed are methods, compositions, devices, and kits for the isolation of brain-specific exosomes. Specifically, methods, compositions, devices, and kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, ?-amyloid, S100 ?, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.

Abstract: Disclosed herein are cerebrospinal fluid (CSF) circulation systems and devices. Also disclosed are methods of using the systems and devices for the processing of CSF and for the treatment of brain or central nervous system diseases, disorders, and injuries. In particular, CSF may be processed to remove various molecules targets, including viruses, bacteria, exosomes, cells, proteins, debris, toxins, and inflammatory mediators. CSF may also be warmed, cooled, and/or oxygenated, and medications or substances may be added to the CSF for targeted treatment of a disease or disorder.

Abstract: An aircraft includes a first engine that generates first bleed air flow and a second engine that generates second bleed air flow. The aircraft further includes an aircraft environmental control system (ECS) with a bleed manifold to collect the first bleed air flow and the second bleed air flow, and one or more air cycle machines to perform air conditioning consuming bleed air flow from the bleed manifold. The ECS balances the first bleed air flow and the second bleed air flow output from the first engine and second engine, respectively, based on a bleed manifold pressure of the bleed manifold.

Abstract: Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines.

Abstract: Pre-authorized communication services and/or transactions are provided via a plurality of networks in response to a request received from a user to provide at least one of a communication service, a transaction and user account information via a plurality of networks of different types. Prior to processing the request, there is verification of the user's authorization to receive the at least one of the communication service, the transaction, and the user account information, and that an account associated with the user has a sufficient amount currently available for payment of the at least one of the communication service and the transaction. After verification, an authorized account associated with the user is charged in real time as the at least one of the communication service and the transaction is provided.